|

Identification and Description of Patients With High-risk Non Metastatic RCC

RECRUITINGSponsored by University Hospital, Bordeaux
Actively Recruiting
SponsorUniversity Hospital, Bordeaux
Started2026-04-17
Est. completion2028-04-17
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07753343

Summary

Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult patients diagnosed with local RCC or high-risk locally advanced RCC,
* Included in UroCCR register between 1st january 2014 and 31st december 2023,
* Consenting to participate in UroCCR and UroCCR-Chain registers.

Exclusion Criteria:

* Patients with metastatic disease at inclusion,
* Patients not linked between UroCCR and SNDS datasources,
* Patients with hereditary RCC.

Conditions2

CancerRenal Cell Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.